The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

Mog  -  myelin oligodendrocyte glycoprotein

Mus musculus

Synonyms: B230317G11Rik, Myelin-oligodendrocyte glycoprotein
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Mog


High impact information on Mog


Chemical compound and disease context of Mog


Biological context of Mog


Anatomical context of Mog

  • This passively induced disease was clinically silent, as was also reported for Lewis rats injected with T cells specific for the same MOG peptide.(ABSTRACT TRUNCATED AT 400 WORDS)[15]
  • We recently demonstrated a predominant response to MOG by peripheral blood lymphocytes from patients with MS tested for their reactivity against various myelin antigens, including MBP and PLP [15].
  • The number of Foxp3(+) cells increased in the spinal cords of mice treated with ES-DC-TRAIL/MOG [18].
  • This preventive effect diminished, if the function of CD4(+)CD25(+) regulatory T cells (Treg) was abrogated by the injection of anti-CD25 mAb into mice before treatment with ES-DC-TRAIL/MOG [18].
  • In addition, another myelin protein, MOG, can also modulate neurite outgrowth [19].

Associations of Mog with chemical compounds


Physical interactions of Mog


Regulatory relationships of Mog


Other interactions of Mog


Analytical, diagnostic and therapeutic context of Mog


  1. Encephalitogenic epitopes of myelin basic protein, proteolipid protein, myelin oligodendrocyte glycoprotein for experimental allergic encephalomyelitis induction in Biozzi ABH (H-2Ag7) mice share an amino acid motif. Amor, S., O'Neill, J.K., Morris, M.M., Smith, R.M., Wraith, D.C., Groome, N., Travers, P.J., Baker, D. J. Immunol. (1996) [Pubmed]
  2. A structurally available encephalitogenic epitope of myelin oligodendrocyte glycoprotein specifically induces a diversified pathogenic autoimmune response. Bischof, F., Bins, A., Dürr, M., Zevering, Y., Melms, A., Kruisbeek, A.M. J. Immunol. (2004) [Pubmed]
  3. Molecular mimicry between a viral peptide and a myelin oligodendrocyte glycoprotein peptide induces autoimmune demyelinating disease in mice. Mokhtarian, F., Zhang, Z., Shi, Y., Gonzales, E., Sobel, R.A. J. Neuroimmunol. (1999) [Pubmed]
  4. The development of autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein is associated with an upregulation of both proinflammatory and immunoregulatory cytokines in the central nervous system. Okuda, Y., Sakoda, S., Bernard, C.C., Yanagihara, T. J. Interferon Cytokine Res. (1998) [Pubmed]
  5. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. Bettelli, E., Pagany, M., Weiner, H.L., Linington, C., Sobel, R.A., Kuchroo, V.K. J. Exp. Med. (2003) [Pubmed]
  6. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Linker, R.A., Mäurer, M., Gaupp, S., Martini, R., Holtmann, B., Giess, R., Rieckmann, P., Lassmann, H., Toyka, K.V., Sendtner, M., Gold, R. Nat. Med. (2002) [Pubmed]
  7. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Liu, J., Marino, M.W., Wong, G., Grail, D., Dunn, A., Bettadapura, J., Slavin, A.J., Old, L., Bernard, C.C. Nat. Med. (1998) [Pubmed]
  8. Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. Marusic, S., Leach, M.W., Pelker, J.W., Azoitei, M.L., Uozumi, N., Cui, J., Shen, M.W., DeClercq, C.M., Miyashiro, J.S., Carito, B.A., Thakker, P., Simmons, D.L., Leonard, J.P., Shimizu, T., Clark, J.D. J. Exp. Med. (2005) [Pubmed]
  9. Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. Kihara, Y., Ishii, S., Kita, Y., Toda, A., Shimada, A., Shimizu, T. J. Exp. Med. (2005) [Pubmed]
  10. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. Ben-Nun, A., Mendel, I., Bakimer, R., Fridkis-Hareli, M., Teitelbaum, D., Arnon, R., Sela, M., Kerlero de Rosbo, N. J. Neurol. (1996) [Pubmed]
  11. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Schori, H., Kipnis, J., Yoles, E., WoldeMussie, E., Ruiz, G., Wheeler, L.A., Schwartz, M. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  12. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Feinstein, D.L., Galea, E., Gavrilyuk, V., Brosnan, C.F., Whitacre, C.C., Dumitrescu-Ozimek, L., Landreth, G.E., Pershadsingh, H.A., Weinberg, G., Heneka, M.T. Ann. Neurol. (2002) [Pubmed]
  13. Functional analysis of the mouse myelin/oligodendrocyte glycoprotein gene promoter in the oligodendroglial CG4 cell line. Solly, S.K., Daubas, P., Monge, M., Dautigny, A., Zalc, B. J. Neurochem. (1997) [Pubmed]
  14. Cutting edge: C3, a key component of complement activation, is not required for the development of myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis in mice. Calida, D.M., Constantinescu, C., Purev, E., Zhang, G.X., Ventura, E.S., Lavi, E., Rostami, A. J. Immunol. (2001) [Pubmed]
  15. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes. Kerlero de Rosbo, N., Mendel, I., Ben-Nun, A. Eur. J. Immunol. (1995) [Pubmed]
  16. Phase separation of myelin proteins in triton X-114: differential behavior of myelin basic protein in purified myelin and in cultured oligodendrocytes. Bürgisser, P., Matthieu, J.M. Dev. Neurosci. (1989) [Pubmed]
  17. Mhc class I and non-class I gene organization in the proximal H2-M region of the mouse. Jones, E.P., Kumánovics, A., Yoshino, M., Fischer Lindahl, K. Immunogenetics (1999) [Pubmed]
  18. Involvement of Regulatory T Cells in the Experimental Autoimmune Encephalomyelitis-Preventive Effect of Dendritic Cells Expressing Myelin Oligodendrocyte Glycoprotein plus TRAIL. Hirata, S., Matsuyoshi, H., Fukuma, D., Kurisaki, A., Uemura, Y., Nishimura, Y., Senju, S. J. Immunol. (2007) [Pubmed]
  19. MAG and MOG enhance neurite outgrowth of embryonic mouse spinal cord neurons. Turnley, A.M., Bartlett, P.F. Neuroreport (1998) [Pubmed]
  20. Streptococcus pneumoniae Infection aggravates experimental autoimmune encephalomyelitis via Toll-like receptor 2. Herrmann, I., Kellert, M., Schmidt, H., Mildner, A., Hanisch, U.K., Brück, W., Prinz, M., Nau, R. Infect. Immun. (2006) [Pubmed]
  21. Myelin/oligodendrocyte glycoprotein (MOG) expression is associated with myelin deposition. Solly, S.K., Thomas, J.L., Monge, M., Demerens, C., Lubetzki, C., Gardinier, M.V., Matthieu, J.M., Zalc, B. Glia (1996) [Pubmed]
  22. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Kataoka, H., Sugahara, K., Shimano, K., Teshima, K., Koyama, M., Fukunari, A., Chiba, K. Cell. Mol. Immunol. (2005) [Pubmed]
  23. Antibodies to myelin/oligodendrocyte-specific protein and myelin/oligodendrocyte glycoprotein signal distinct changes in the organization of cultured oligodendroglial membrane sheets. Dyer, C.A., Matthieu, J.M. J. Neurochem. (1994) [Pubmed]
  24. Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis. Sahrbacher, U.C., Lechner, F., Eugster, H.P., Frei, K., Lassmann, H., Fontana, A. Eur. J. Immunol. (1998) [Pubmed]
  25. ERK1-deficient mice show normal T cell effector function and are highly susceptible to experimental autoimmune encephalomyelitis. Nekrasova, T., Shive, C., Gao, Y., Kawamura, K., Guardia, R., Landreth, G., Forsthuber, T.G. J. Immunol. (2005) [Pubmed]
  26. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. Becher, B., Durell, B.G., Noelle, R.J. J. Clin. Invest. (2003) [Pubmed]
  27. Resistance to myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis by death receptor 6-deficient mice. Schmidt, C.S., Zhao, J., Chain, J., Hepburn, D., Gitter, B., Sandusky, G., Chintalacharuvu, S., Glasebrook, A., Na, S. J. Immunol. (2005) [Pubmed]
  28. Experimental autoimmune encephalomyelitis in intercellular adhesion molecule-1-deficient mice. Samoilova, E.B., Horton, J.L., Chen, Y. Cell. Immunol. (1998) [Pubmed]
  29. Protection from autoimmune brain inflammation in mice lacking IFN-regulatory factor-1 is associated with Th2-type cytokines. Buch, T., Uthoff-Hachenberg, C., Waisman, A. Int. Immunol. (2003) [Pubmed]
  30. Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response. Lobell, A., Weissert, R., Eltayeb, S., de Graaf, K.L., Wefer, J., Storch, M.K., Lassmann, H., Wigzell, H., Olsson, T. J. Immunol. (2003) [Pubmed]
  31. Antibody association with a novel model for primary progressive multiple sclerosis: induction of relapsing-remitting and progressive forms of EAE in H2s mouse strains. Tsunoda, I., Kuang, L.Q., Theil, D.J., Fujinami, R.S. Brain Pathol. (2000) [Pubmed]
WikiGenes - Universities